Presentation Outline ICHP Annual Meeting September 13-15

More documents

Recommendations

Info

Findings and Scope of Problem • UHC and phone interviews – Baseline evaluation of policies • 8 of 18 kept patients on their home pumps • 10 of 18 patients did not keep back-up prostacyclin cassettes on the unit Kingman MS, et al. J Heart Lung Transplant. 2010;29:841-846. Findings and Scope of Problem • Phone interview – Serious errors at 17 of 18 centers • Failure to restart CADD pump • Wrong patient • Wrong rate • Errors in dose calculations • Flushing of the prostacyclin line – 3 deaths CADD, computerized ambulatory drug delivery Kingman MS, et al. J Heart Lung Transplant. 2010;29:841-846. Findings and Scope of Problem • Electronic survey – Serious or potentially serious errors – 68% • Wrong patient • Wrong dose • Pump left off • Flushing the line – 9 deaths Kingman MS, et al. J Heart Lung Transplant. 2010;29:841-846. 4
Examples of Medication Considerations Treprostinil • Multiple vial concentrations – 1, 2.5, 5, & 10 mg/mL • Multiple routes of administration – IV, SC, inhaled • Multiple delivery systems – IV – CADD infusion pump, Crono-5 pump – SC – CADD-MS3 & MiniMed syringe pumps – Inhaled – Tyvaso inhalation system ® Examples of Medication Considerations Epoprostenol • Requires reconstitution • Requires back-up cassette • Multiple formulations – Epoprostenol (Flolan ® ) – Generic epoprostenol – “Room-temperature stable” epoprostenol (Veletri ® ) Knowing the Pharmacist’s Role in Managing PAH Pathophysiology of PAH Heather R. Bream-Rouwenhorst, PharmD, BCPS Clinical Assistant Professor University of Iowa College of Pharmacy Clinical Pharmacy Specialist – Cardiology University of Iowa Hospitals and Clinics Iowa City, IA 5
Page 1 and 2: ACTIVITY DESCRIPTION Target Audienc
Page 3: Current Challenges • Expansion of
Page 7 and 8: Etiology (Dana Point, 2008) 1’. P
Page 9 and 10: PAH Therapy Targets Schulze-Neick I
Page 11 and 12: Chronic Adjuvant Therapies in PAH D
Page 13 and 14: Cummulative suurvival Survival in I
Page 15 and 16: ACCF/AHA Consensus PAH Treatment Al
Page 17 and 18: Study Name Drug SUPER-1 Oral silden
Page 19 and 20: IV Epoprostenol in PAH Due to Scler
Page 21 and 22: 70 60 50 40 30 20 10 Inhaled Ilopro
Page 23 and 24: Conclusions • PAH therapy improve
Page 25 and 26: ESC/ERS Guidelines Galie N, et al.
Page 27 and 28: FUTURE DIRECTIONS WHICH MAY IMPACT
Page 29 and 30: Rationale for “Front-Loaded” Ap
Page 31 and 32: Addressing gthe Challenges g in PAH
Page 33 and 34: Considerations • Central vs. peri
Page 35 and 36: Pulmonary Hypertension • Approxim
Page 37 and 38: Example Cassette Calculations • V
Page 39 and 40: Assessment Question 1 Which of the
Page 41 and 42: Illinois Council of Health‐System
Page 43 and 44: Patient Activity ‐ 1 Patients in
Page 45 and 46: Hospitalists National Trends • Ja
Page 47 and 48: Pharmacy Landscape • PGY‐2: So
Page 49 and 50: Primary Care Physicians by Field, F
Page 51 and 52: Health Systems Pharmacy and TATAI
Page 53 and 54: Readings The 21 Irrefutable Laws of
Page 55 and 56:
What is a “Practice Model”? •
Page 57 and 58:
Completing the Self Assessment •
Page 59 and 60:
Residency trained (B23p) Illinois N
Page 61 and 62:
Solving the PPMI Puzzle ‐ Here Ar
Page 63 and 64:
Overview of Value Based Purchasing
Page 65 and 66:
Implementation of Medication‐ rel
Page 67 and 68:
Question #1 Within which programs a
Page 69 and 70:
Solving the PPMI Puzzle‐ Here are
Page 71 and 72:
Discharge Education/Med Rec • New
Page 73 and 74:
Media‐Worthy Trials? Making Sense
Page 75 and 76:
Prevention of Recurrent VTE • Unp
Page 77 and 78:
VTE recurrence during study period
Page 79 and 80:
Which patient might be a candidate
Page 81 and 82:
Azithromycin and CV Death • Endpo
Page 83 and 84:
Azithromycin and CV Death Azithromy
Page 85 and 86:
Hormonal Contraception and VTE •
Page 87 and 88:
• Age • Calendar year • Educa
Page 89 and 90:
ARR=2.20, 2.28 for stroke, MI when
Page 91 and 92:
Which of the following combinations
Page 93 and 94:
3 Months of Treatment for Latent TB
Page 95 and 96:
3 Months of Treatment for Latent TB
Page 97 and 98:
T/F: Rifapentine in combination wit
Page 99 and 100:
2. Which of the following statement
Page 101 and 102:
Fitting the Counseling Piece into M
Page 103 and 104:
Current Evidence: Implementing Bund
Page 105 and 106:
Teach Back Process • Step 1 Expla
Page 107 and 108:
Questions for Consideration and Dis
Page 109 and 110:
Why do we care about ADE? • Adver
Page 111 and 112:
True or False • Medication errors
Page 113 and 114:
Check Point Which of the following
Page 115 and 116:
Proactive Screening Process Patient
Page 117 and 118:
MTI Pilot at NAH PharmD Students tr
Page 119 and 120:
ASHP PPMI Case Study Adding Value:
Page 121 and 122:
Interdisciplinary Teamwork: How Phy
Page 123 and 124:
Highly Effective Healthcare • Wha
Page 125 and 126:
Inter‐Professional Teams ‐ Chan
Page 127 and 128:
Meeting the PPMI Goals for Technolo
Page 129 and 130:
Drug‐Bug Mismatch Example Con’t
Page 131 and 132:
Drug‐Bug Mismatch Build Rules •
Page 133 and 134:
Page 135 and 136:
Patient Scanning Compliance Sample
Page 137 and 138:
Page 139 and 140:
Global Immunizations 3 • Jan 2012
Page 141 and 142:
Mobile Devices: Beyond Angry Birds
Page 143 and 144:
Google Play • Google Play - Inter
Page 145 and 146:
Other Useful Productivity Apps •
Page 147 and 148:
Mobile Devices: Beyond Angry Birds
Page 149 and 150:
Net Activations by Industry Source:
Page 151 and 152:
News Readers/Aggregators Features S
Page 153 and 154:
Contact Information • E‐mail: -
Page 155 and 156:
Early‐Onset Sepsis • Sign and s
Page 157 and 158:
• BR is on day 2 of cefotaxime wi
Page 159 and 160:
Immunizations: The Superheroes to P
Page 161 and 162:
Current ACIP Recommendations Influe
Page 163 and 164:
Herpes Zoster Vaccine Recommendatio
Page 165 and 166:
Assessment Questions 1. What are th
Page 167 and 168:
HIV Linkage and Retention in Care T
Page 169 and 170:
DHHS Guidelines, March 2012: When t
Page 171 and 172:
Protease Inhibitors • Require “
Page 173 and 174:
Mean Change (mg/ /dL) STARTMRK: Lip
Page 175 and 176:
RAL Drug Interactions • Does not
Page 177 and 178:
Instructions for Credit In order to
Page 179 and 180:
Staging Stage Criteria (Durie‐Sal
Page 181 and 182:
Salvage Therapy Partial List Regime
Page 183 and 184:
Bortezomib-Thalidomide-Dexamethason
Page 185 and 186:
Case 2 ST is a 76 y/o African Ameri
Page 187 and 188:
Thalidomide and Lenalidomide • Ad
Page 189 and 190:
Fixed Low-Dose Warfarin Study Thera
Page 191 and 192:
New Drugs 2012 Anna Nowobilski‐Va
Page 193 and 194:
Pulmonology » Cystic Fibrosis •
Page 195 and 196:
Oncology » MTX Toxicity • MTX 1o
Page 197 and 198:
NEW DRUGS AND BIOLOGICALS 2012 RESO
Page 199 and 200:
Disease State Reviews for Pharmacy
Page 201 and 202:
Chronic Obstructive Pulmonary Disea
Page 203 and 204:
Page 205 and 206:
Green Zone • Patient is not havin
Page 207 and 208:
Page 209 and 210:
• A hormone produced by the pancr
Page 211 and 212:
Unraveling Unraveling The The Puzzl
Page 213 and 214:
The Reward Center In time, serious
Page 215 and 216:
So what makes addicted pharmacists
Page 217 and 218:
How to find a treatment center Onli
Page 219 and 220:
Internet Drug Abuse Study conducted
Page 221 and 222:
NIAAA = best resource for alcohol d
Page 223 and 224:
Impact of Postoperative Pain • Pi
Page 225 and 226:
Safety Profile • Amar et al confi
Page 227 and 228:
References 1. Rømsing J, Møiniche
Page 229 and 230:
Society of Regional Anesthesia Meet
Page 231 and 232:
A New Approach IV Acetaminophen •
Page 233 and 234:
References • Schechter, Leslie N.
Page 235 and 236:
Bupivacaine liposome injectable sus
Page 237 and 238:
Error Potential • Inadvertent IV
Page 239 and 240:
Decolonization Methods • Anti-sep
Page 241 and 242:
Evidence: Inpatient ICU MRSA Coloni
Page 243 and 244:
Residency Project Pearls Adherence
Page 245 and 246:
650 subjects id identified tifi d R
Page 247 and 248:
Overtreatment versus Appropriate Tr
Page 249 and 250:
Adherence to and Outcomes Associate
Page 251 and 252:
Background • Lack of comprehensiv
Page 253 and 254:
Results Results‐User User Audits
Page 255 and 256:
Special thanks to: • Carol Heunis
Page 257 and 258:
Antibiotic Prophylaxis American Hea
Page 259 and 260:
Study Limitations • Dependent on
Page 261 and 262:
Study Background • Observation of
Page 263 and 264:
A patient has a CrCl of 25 mL/min.
Page 265 and 266:
• Cysteine hydrochloride: antioxi
Page 267 and 268:
Sample Preparation • Intravenous
Page 269 and 270:
Questions? Residency Project Pearls
Page 271 and 272:
The Interview: Your Preparation •
Page 273 and 274:
PGY1 Residency Options Carol Heunis
Page 275 and 276:
RESIDENCY PROGRAM BASICS • Progra
Page 277 and 278:
CV: The key to a top curriculum vit
Page 279 and 280:
Tips for a Top Notch CV • Focus o
Page 281 and 282:
What is PhORCAS? • PhORCAS is the
Page 283 and 284:
Piecing together the new CHEST guid
Page 285 and 286:
Initiating therapy CHEST 2012 2.1.8
Page 287 and 288:
What is “Consistently Stable?”
Page 289 and 290:
Puzzle # 2A: patient has just compl
Page 291 and 292:
What would you do for JJ? • A. Ho
Page 293 and 294:
Considerations for SB • Bleeding
show all

Presentation Outline ICHP Annual Meeting September 13-15

Create successful ePaper yourself

Delete template?

Save as template?